Related references
Note: Only part of the references are listed.Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial
Yutaka Osuga et al.
FERTILITY AND STERILITY (2021)
Epidemiology and management of uterine fibroids
Emma Giuliani et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2020)
Ulipristal acetate for Japanese women with symptomatic uterine fibroids: A double-blind, randomized, phase II dose-finding study
Minoru Irahara et al.
REPRODUCTIVE MEDICINE AND BIOLOGY (2020)
Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas A Randomized Controlled Trial
Yutaka Osuga et al.
OBSTETRICS AND GYNECOLOGY (2019)
Ulipristal Acetate Interferes With Actin Remodeling Induced by 17 beta-Estradiol and Progesterone in Human Endometrial Stromal Cells
Jorge E. Shortrede et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program
Jacques Donnez et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results
Herve Fernandez et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2017)
Safety after extended repeated use of ulipristal acetate for uterine fibroids
Bart C. J. M. Fauser et al.
PLOS ONE (2017)
In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment
Guillaume E. Courtoy et al.
FERTILITY AND STERILITY (2015)
Disease history and risk of comorbidity in women's life course: a comprehensive analysis of the Japan Nurses' Health Study baseline survey
Kazue Nagai et al.
BMJ OPEN (2015)
Long-term treatment of uterine fibroids with ulipristal acetate
Jacques Donnez et al.
FERTILITY AND STERILITY (2014)
Burden of menstrual symptoms in Japanese women: results from a survey-based study
Erika Tanaka et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Endometrial Morphology After Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator, Ulipristal Acetate
Alistair R. W. Williams et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Jacques Donnez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids
Jacques Donnez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women
Anne Zimmermann et al.
BMC WOMENS HEALTH (2012)
Initial Experience of Uterine Fibroid Embolization Using Porous Gelatin Sponge Particles
Tetsuya Katsumori et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2011)
Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebo-controlled trial
Nathalie Chabbert-Buffet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Racial differences in premenopausal endogenous hormones
SP Pinheiro et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914
BJ Attardi et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2002)
Share Paper
